{
 "as_of": "2026-11-08",
 "cmr": "us-cm-kg/NASDAQ/ELOX",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) — research page\n\nAs of 2026-11-08 · us-cm-kg · record version 1\n\n## Identity and listing\n\nEloxx Pharmaceuticals, Inc. is listed on NASDAQ under ticker ELOX, ISIN US29014R3012, LEI 549300UB28QGWJMFFA11. Its security type is Corporate. The segment is not on the record. Its sector is 2836 Biological Products, (No Diagnostic Substances), and its jurisdiction is United States — Delaware. Its listing status is listed, not halted.\n\n## The disclosure read\n\nThe record holds 50 filings in the twelve months to 2026-11-08, across 25 filing days. The median gap between filing days is 3.0 days. The latest filing is dated 2026-10-22, 17 days before the record date, and is of type prospectus. The NASDAQ median cadence gap is 6.0 days across 4359 issuers, and the sector median cadence gap is 5.5 days across 176 issuers. The NASDAQ median is 52 filings and the sector median is 65.5 filings in the same window. The NASDAQ median latency is 5.0 days and the sector median latency is 4.0 days. By type, the record holds 18 directors dealings, 19 regulatory filings, 6 prospectuses, 4 results, 2 director changes and 1 AGM/EGM filing.\n\n## Auditor\n\nThe auditor of record is not on the record, because the latest annual report cover carries no dei:AuditorName tag. The auditor's location is not on the record. The record holds no auditor changes.\n\n## Events and halts\n\nThe record holds two listing lines, dated 2026-06-01 and 2026-06-08. It holds no delisting, no name change, and no segment move. The domicile change is not on the record, because EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, because the exchanges' tier transfers are not EDGAR filings. The halt flag reads listed, not halted.\n\n## Orderability\n\nThe outcome is not determinable for this issuer under acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, as of 2026-11-04. The chapter's orderability section carries no client categories, so the outcome cannot name its client category.\n\n## Coverage\n\nThe issuer's own investor-relations page names five research houses: Cantor Fitzgerald, Guggenheim Securities, Leerink Partners, LifeSci Capital and Lucid Capital Markets.\n\n## Open research\n\nNo openly published research notes were found on the record.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe record holds sealed filings for this issuer for the years 2021, 2022, 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12.\n\n## Sources\n\n9 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange)\n- https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data (identity.isin)\n- https://data.sec.gov/submissions/CIK0001035354.json (identity.jurisdiction)\n- https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei)\n- https://mcp.us-cm-kg.ai/events/NASDAQ/ELOX (the disclosure lines)\n- https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag)\n- https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://www.eloxxpharma.com/investors/ (coverage)\n- https://mcp.us-cm-kg.ai/record/NASDAQ/ELOX (the record)\n",
 "market": "US",
 "node": "us-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "live_record_began": "2026-09-12",
   "node_history_from": "2021-01-04",
   "node_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "record_version": 1,
   "sealed": true
  },
  "auditor": {
   "auditor": {
    "market": "US",
    "reason": "no dei:AuditorName tag on the latest annual report cover (foreign private issuers and older filings carry none)",
    "state": "not_on_record"
   },
   "auditor_firm_id": {
    "market": "US",
    "state": "not_on_record"
   },
   "auditor_location": {
    "market": "US",
    "state": "not_on_record"
   },
   "changes": []
  },
  "cmr": "us-cm-kg/NASDAQ/ELOX",
  "coverage": {
   "count": 5,
   "houses": [
    {
     "analyst": "Yanni Souroutzidis",
     "house": "Cantor Fitzgerald",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://www.eloxxpharma.com/investors/",
     "state": "sourced"
    },
    {
     "analyst": "Vamil Divan, M.D.",
     "house": "Guggenheim Securities",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://www.eloxxpharma.com/investors/",
     "state": "sourced"
    },
    {
     "analyst": "Joseph Schwartz",
     "house": "Leerink Partners",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://www.eloxxpharma.com/investors/",
     "state": "sourced"
    },
    {
     "analyst": "Rami Katkhuda",
     "house": "LifeSci Capital",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://www.eloxxpharma.com/investors/",
     "state": "sourced"
    },
    {
     "analyst": "Dev Prasad, Ph.D.",
     "house": "Lucid Capital Markets",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://www.eloxxpharma.com/investors/",
     "state": "sourced"
    }
   ],
   "pages_checked": [
    {
     "page": "https://www.eloxxpharma.com/investors/",
     "result": "read: 5 of 10 named houses found on the page"
    }
   ],
   "read_by": "Perplexity sonar (search) · page read by this rail",
   "read_date": "2026-11-11",
   "since": "not stated on the page read",
   "state": "found"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 4359,
     "median_cadence_gap_days": 6,
     "median_filings": 52,
     "median_latency_days": 5,
     "name": "NASDAQ"
    },
    "sector": {
     "issuers": 176,
     "median_cadence_gap_days": 5.5,
     "median_filings": 65.5,
     "median_latency_days": 4,
     "name": "2836 Biological Products, (No Diagnostic Substances)"
    }
   },
   "by_type": {
    "agm_egm": 1,
    "director_change": 2,
    "directors_dealings": 18,
    "prospectus": 6,
    "regulatory_filing": 19,
    "results": 4
   },
   "cadence_median_gap_days": 3,
   "filing_days": 25,
   "filings": 50,
   "latency_days": 17,
   "latest": [
    {
     "category": "424B3",
     "date": "2026-10-22",
     "source": "https://www.sec.gov/Archives/edgar/data/1035354/000119312526428120/d462611d424b3.htm",
     "title": "424B3 — 424B3",
     "type": "prospectus"
    },
    {
     "category": "8-K",
     "date": "2026-10-22",
     "source": "https://www.sec.gov/Archives/edgar/data/1035354/000119312526428116/d462611d8k.htm",
     "title": "8-K — 8-K (items 5.02,8.01)",
     "type": "director_change"
    },
    {
     "category": "4",
     "date": "2026-10-21",
     "source": "https://www.sec.gov/Archives/edgar/data/1035354/000119312526428121/xslF345X06/ownership.xml",
     "title": "4 — 4",
     "type": "directors_dealings"
    },
    {
     "category": "3",
     "date": "2026-10-21",
     "source": "https://www.sec.gov/Archives/edgar/data/1035354/000119312526428118/xslF345X06/ownership.xml",
     "title": "3 — 3",
     "type": "directors_dealings"
    },
    {
     "category": "EFFECT",
     "date": "2026-09-18",
     "source": "https://www.sec.gov/Archives/edgar/data/1035354/999999999526003014/xslEFFECTX01/primary_doc.xml",
     "title": "EFFECT (items ,,)",
     "type": "regulatory_filing"
    }
   ],
   "latest_filing_date": "2026-10-22",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.us-cm-kg.ai/events/NASDAQ/ELOX",
   "window": {
    "from": "2025-11-08",
    "to": "2026-11-08"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "NASDAQ"
   },
   "isin": {
    "read_by": "SEC Fails-to-Deliver data (CUSIP for the symbol) · ISIN = US + CUSIP + ISO 6166 check digit",
    "read_date": "2026-10-14",
    "read_date_basis": "last_seen",
    "source": "https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data",
    "state": "sourced",
    "value": "US29014R3012"
   },
   "jurisdiction": {
    "read_by": "EDGAR submissions API (issuer header as filed) (stateOfIncorporation)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001035354.json",
    "state": "sourced",
    "value": "United States — Delaware"
   },
   "lei": {
    "read_by": "GLEIF ISIN-to-LEI mapping file (daily), LEI by exact ISIN",
    "read_date": "2026-11-08",
    "read_date_basis": "the field",
    "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download (ISIN US29014R3012)",
    "state": "sourced",
    "value": "549300UB28QGWJMFFA11"
   },
   "name": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001035354.json",
    "state": "sourced",
    "value": "Eloxx Pharmaceuticals, Inc."
   },
   "sector": {
    "read_by": "EDGAR submissions API (issuer header as filed) (SIC code as assigned by the SEC)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001035354.json",
    "state": "sourced",
    "value": "2836 Biological Products, (No Diagnostic Substances)"
   },
   "security_type": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001035354.json",
    "state": "sourced",
    "value": "Corporate"
   },
   "segment": {
    "market": "US",
    "state": "not_on_record"
   },
   "ticker": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "ELOX"
   },
   "website": {
    "market": "US",
    "state": "not_on_record"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": [],
   "domicile_change": {
    "market": "US",
    "reason": "EDGAR states no dated change of state of incorporation on a filing line",
    "state": "not_on_record"
   },
   "listing": [
    {
     "date": "2026-06-01",
     "source": "https://www.sec.gov/Archives/edgar/data/1035354/000119312526251780/d75472d8a12b.htm",
     "title": "8-A12B — 8-A12B"
    },
    {
     "date": "2026-06-08",
     "source": "https://www.sec.gov/Archives/edgar/data/1035354/000135445726000547/ELOX_8A_Cert_1035354.pdf",
     "title": "CERT"
    }
   ],
   "name_change": [],
   "segment_move": {
    "market": "US",
    "reason": "the exchanges' tier transfers are not EDGAR filings",
    "state": "not_on_record"
   }
  },
  "market": "US",
  "node": "us-cm-kg",
  "numbers_hash": "sha256:d91a9848750030733ca6d78a3ab1bbfb6ab76fa00fb368398706b98238ea060f",
  "open_research": {
   "read_date": "2026-11-11",
   "rows": [],
   "state": "none_found"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [],
   "determinable": false,
   "read": {
    "chapter": "https://mcp.us-cm-kg.ai/book/aio.json",
    "door": "https://mcp.us-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "reason": "the chapter's orderability section carries no client_categories: the outcome cannot name its client category",
   "rule_version": "acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1",
   "section": "us.aio.v8"
  },
  "record": {
   "as_of": "2026-11-08",
   "url": "https://mcp.us-cm-kg.ai/record/NASDAQ/ELOX",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "read_date": "2026-11-08",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts",
   "value": "listed, not halted"
  }
 },
 "numbers_hash": "sha256:d91a9848750030733ca6d78a3ab1bbfb6ab76fa00fb368398706b98238ea060f",
 "path": "/us/NASDAQ/ELOX",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "Eloxx Pharmaceuticals, Inc. is listed on NASDAQ under ticker ELOX, ISIN US29014R3012, LEI 549300UB28QGWJMFFA11. Its security type is Corporate. The segment is not on the record. Its sector is 2836 Biological Products, (No Diagnostic Substances), and its jurisdiction is United States — Delaware. Its listing status is listed, not halted.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 50 filings in the twelve months to 2026-11-08, across 25 filing days. The median gap between filing days is 3.0 days. The latest filing is dated 2026-10-22, 17 days before the record date, and is of type prospectus. The NASDAQ median cadence gap is 6.0 days across 4359 issuers, and the sector median cadence gap is 5.5 days across 176 issuers. The NASDAQ median is 52 filings and the sector median is 65.5 filings in the same window. The NASDAQ median latency is 5.0 days and the sector median latency is 4.0 days. By type, the record holds 18 directors dealings, 19 regulatory filings, 6 prospectuses, 4 results, 2 director changes and 1 AGM/EGM filing.",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor of record is not on the record, because the latest annual report cover carries no dei:AuditorName tag. The auditor's location is not on the record. The record holds no auditor changes.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "The record holds two listing lines, dated 2026-06-01 and 2026-06-08. It holds no delisting, no name change, and no segment move. The domicile change is not on the record, because EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, because the exchanges' tier transfers are not EDGAR filings. The halt flag reads listed, not halted.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "The outcome is not determinable for this issuer under acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, as of 2026-11-04. The chapter's orderability section carries no client categories, so the outcome cannot name its client category.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "The issuer's own investor-relations page names five research houses: Cantor Fitzgerald, Guggenheim Securities, Leerink Partners, LifeSci Capital and Lucid Capital Markets.",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "No openly published research notes were found on the record.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "The record holds sealed filings for this issuer for the years 2021, 2022, 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "9 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://www.sec.gov/files/company_tickers_exchange.json"
  },
  {
   "for": "identity.isin",
   "source": "https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data"
  },
  {
   "for": "identity.jurisdiction",
   "source": "https://data.sec.gov/submissions/CIK0001035354.json"
  },
  {
   "for": "identity.lei",
   "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.us-cm-kg.ai/events/NASDAQ/ELOX"
  },
  {
   "for": "the halt flag",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts"
  },
  {
   "for": "the orderability chapter",
   "source": "https://mcp.us-cm-kg.ai/book/aio.json"
  },
  {
   "for": "coverage",
   "source": "https://www.eloxxpharma.com/investors/"
  },
  {
   "for": "the record",
   "source": "https://mcp.us-cm-kg.ai/record/NASDAQ/ELOX"
  }
 ],
 "title": "Eloxx Pharmaceuticals, Inc. (ELOX) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}